Search Results

The Myglucohealth glucose monitoring system provides a quick and easy way for diabetic patients to measure and self-monitor blood glucose levels. The system is comprised of the MGH-BT1 (w/Bluetooth wireless download capability) or the MGH-1 (w/o Bluetooth) blood glucose meter, control solution and test strips that carry a biosensor used for the quantitative measurement of the concentration of glucose in capillary whole blood that can be taken from the fingertip, ventral palm, hand, upper arm, forearm, calf and/or thigh by diabetic patients or health care professionals. The results obtained are plasma calibrated to allow for easy comparison to the laboratory method. Further, results from either meter may be uploaded to a memory device through a standard RS32 connection, or, with the-BT1 model, wirelessly transmitted to a bluetooth capable PC or Cell phone. The Myglucohealth glucose monitoring systems are not to be used for the diagnosis or screening of diabetes or for neonatal use. Alternate site testing should be done during steady-state times when glucose is not changing rapidly.

Systems are intended for the quantitative measurement of the concentration of glucose in whole blood that can be taken from the fingertip, ventral palm, dorsal hand, upper arm, forearm, calf and/or thigh by diabetic patients or health care professionals. Results are plasma calibrated to allow for easy comparison to lab method. The Myglucohealth glucose monitoring systems are not to be used for the diagnosis of diabetes or for neonatal use. Alternate site testing should be done during steady-state times when glucose is not changing rapidly.

The provided document is a 510(k) premarket notification for the Myglucohealth Glucose Monitoring System. It focuses on demonstrating substantial equivalence to a predicate device rather than providing a detailed clinical study report with specific acceptance criteria and performance data in the format requested.

Therefore, the requested tables and specific details about acceptance criteria and study data (like sample sizes, ground truth establishment, expert qualifications, adjudication methods, or MRMC studies) are not fully contained within the provided text.

The document primarily states that the device is equivalent to its predicate by virtue of similar materials, manufacturing methods, and intended use, and validates its wireless data transfer.

However, I can extract information related to what is available and format it to the best of my ability, highlighting where information is missing.

1. Table of Acceptance Criteria and Reported Device Performance

The document states compliance with ISO 15197 for the device in general, and then specifies a "100% correlation to actual monitor data" for the wireless transfer function. ISO 15197 sets accuracy requirements for blood glucose monitoring systems. Without the full ISO 15197 report or a specific excerpt, the precise accuracy criteria and detailed performance (e.g., bias, precision, percentage within specific error margins) cannot be fully reported from this document.

2. Sample Size Used for the Test Set and Data Provenance

• Sample Size for Wireless Transfer Validation: "A significant number of users of varying demographic ages, gender, education and background were studied."
  • Specific number: Not specified in the document.
• Data Provenance: The document does not specify country of origin for the data, nor whether it was retrospective or prospective. It only mentions the "users" were studied, suggesting a prospective study for the wireless transfer validation. For the general device performance and ISO 15197 compliance, the document does not provide details on the study design or data provenance.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

This information is not provided in the document. The document focuses on the technical and regulatory aspects of device equivalence and wireless function validation, not on clinical study details involving experts for ground truth establishment.

4. Adjudication Method for the Test Set

This information is not provided in the document. Since there is no mention of independent expert review or a traditional "test set" in a clinical study sense (beyond the wireless transfer validation), an adjudication method is not described.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No, an MRMC comparative effectiveness study was not performed or mentioned. This type of study is typically for evaluating diagnostic imaging systems or decision support tools where human interpretation is a key component, often comparing human performance with and without AI assistance. The Myglucohealth Glucose Monitoring System is a handheld device for quantitative measurement, which does not involve human interpretation in the same manner.

6. If a Standalone Study (Algorithm Only Without Human-in-the-Loop Performance) Was Done

The wireless data transfer validation could be considered a form of standalone performance assessment for that specific function (algorithm in this case refers to the transmission protocol). It evaluated the system's ability to transfer data accurately without human intervention in the data's content.

• Wireless Data Transfer: A standalone assessment was performed for the wireless uploading of data, demonstrating "100% correlation to actual monitor data."
• Glucose Measurement Performance: The document states compliance with ISO 15197. This standard inherently requires a standalone (device-only) performance evaluation against a reference method. However, the specific study details for this compliance are not provided in the document.

7. The Type of Ground Truth Used

• For Wireless Data Transfer Validation: The "actual monitor data" served as the ground truth. This means the data directly displayed on the device's screen was compared to the wirelessly transmitted data.
• For Glucose Measurement Performance: For ISO 15197 compliance, the ground truth would typically be established by a laboratory reference method (e.g., a highly accurate spectrophotometric method). This is not explicitly stated but is standard practice for such device validations. The document mentions "Results are plasma calibrated to allow for easy comparison to lab method," which supports this inference.

8. The Sample Size for the Training Set

This information is not provided in the document. Blood glucose monitoring systems typically do not involve "training sets" in the machine learning sense for their core measurement function. If firmware or algorithms were optimized, this process is not detailed. The "significant number of users" were likely for validation or verification, not a training set.

9. How the Ground Truth for the Training Set Was Established

This information is not provided in the document as a training set is not explicitly mentioned for the core glucose measurement function.

Ask a specific question about this device